bioMerieux Net Current Debt 2017-2024 | BMXMF
bioMerieux annual/quarterly net current debt history and growth rate from 2017 to 2024. Net current debt can be defined as the net amount of debt repaid and issued with short-term maturities.
- bioMerieux net current debt for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- bioMerieux net current debt for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- bioMerieux annual net current debt for 2024 was $0B, a 0% decline from 2023.
- bioMerieux annual net current debt for 2023 was $0B, a 0% decline from 2022.
- bioMerieux annual net current debt for 2022 was $0B, a 0% decline from 2021.
| bioMerieux Annual Net Current Debt (Millions of US $) |
|
|---|---|
| 2024 | $N/A |
| 2023 | $N/A |
| 2022 | $N/A |
| 2021 | $N/A |
| 2020 | $N/A |
| 2019 | $N/A |
| 2018 | $N/A |
| 2017 | $N/A |
| 2016 | $N/A |
| 2015 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $16.097B | $4.307B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||